Efficacy, safety and tolerability of escitalopram in doses up to 50 mg in Major Depressive Disorder (MDD): an open-label, pilot study

Table 2 Timing and dose at treatment discontinuation

Dose of escitalopram	Week of last completed visit	Number of patients discontinued
		Due to an AE^a	Not due to an AE^a
10 mg	Week 0 (baseline)	6	0
	Week 8	1	0
20 mg	Week 4	1	0
	Week 16	1	0
30 mg	Week 8	1	0
35 mg	Week 8	0	2 (1 - ineligible to continue, 1 - lack of efficacy)
40 mg	Week 24	1	0
45 mg	Week 24	1	1 (lack of efficacy)
50 mg	Week 16	1	0
	Week 20	0	1 (lost to follow up)
	Week 24	0	1 (lack of efficacy)

^a AE: adverse event. The reason for withdrawal was taken from the End of Study Case Report Form (CRF) page. This stated that a patient withdrew due to an AE, although this was not recorded as a withdrawal as a result of an AE on the AE CRF page

ISSN: 1471-244X